Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma.
about
Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.Interleukin-1β mediates metalloproteinase-dependent renal cell carcinoma tumor cell invasion through the activation of CCAAT enhancer binding protein βTivozanib in the treatment of renal cell carcinoma.Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities.
P2860
Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Current status of cytokine the ...... tastatic renal cell carcinoma.
@ast
Current status of cytokine the ...... tastatic renal cell carcinoma.
@en
type
label
Current status of cytokine the ...... tastatic renal cell carcinoma.
@ast
Current status of cytokine the ...... tastatic renal cell carcinoma.
@en
prefLabel
Current status of cytokine the ...... tastatic renal cell carcinoma.
@ast
Current status of cytokine the ...... tastatic renal cell carcinoma.
@en
P2860
P1476
Current status of cytokine the ...... tastatic renal cell carcinoma.
@en
P2093
Anil K Kapoor
Sébastien J Hotte
P2860
P304
P433
P577
2007-06-01T00:00:00Z